ESC Premium Access

Is atrial fibrillation ablation a mature treatment to reduce morbi-mortality?

Event: ESC Congress 2018
Topic: Epidemiology, Prognosis, Outcome
Session type: Symposium
Date: 28 August 2018
Time: 14:30 - 15:45

Congress Session

4 presentations in this session

Effects of atrial fibrillation ablation in patients with stroke risk factors: the CABANA Trial.

Speaker: Doctor D. Packer (Rochester, US)

Effects of atrial fibrillation ablation in patients with lV dysfunction: the CASTE-AF trial.

Speaker: Professor J. Brachmann (Coburg, DE)

Critical appraisal of the CABANA and CASTLE-AF trials.

Speaker: Professor I. Van Gelder (Groningen, NL)

Will the technical improvements in atrial fibrillation ablation further improve the success of atrial fibrillation ablation.

Speaker: Professor G. Hindricks (Leipzig, DE)

4 speakers from this session

Doctor Douglas L Packer

Mayo Clinic Hospital - St. Mary's Campus, Rochester (United States of America)
13 presentations
0 follower

Professor Johannes Brachmann

REGIOMED Clinics Coburg, Coburg (Germany)
8 presentations
0 follower

Professor Isabelle C Van Gelder

University Medical Center Groningen, Groningen (Netherlands (The))
39 presentations

Professor Gerhard Hindricks

Heart Center of Leipzig, Leipzig (Germany)
55 presentations

This platform is supported by

logo Novo Nordisk